PE20221836A1 - Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 - Google Patents
Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5Info
- Publication number
- PE20221836A1 PE20221836A1 PE2022002114A PE2022002114A PE20221836A1 PE 20221836 A1 PE20221836 A1 PE 20221836A1 PE 2022002114 A PE2022002114 A PE 2022002114A PE 2022002114 A PE2022002114 A PE 2022002114A PE 20221836 A1 PE20221836 A1 PE 20221836A1
- Authority
- PE
- Peru
- Prior art keywords
- receptor
- alkyl
- gaba
- alpha5
- compounds
- Prior art date
Links
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 title 1
- DVXYZLCJSYRIPC-UHFFFAOYSA-N pyrido[3,4-c]pyridazine Chemical class C1=NN=C2C=NC=CC2=C1 DVXYZLCJSYRIPC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 102000004300 GABA-A Receptors Human genes 0.000 abstract 2
- 108090000839 GABA-A Receptors Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- -1 -tert-butyl carboxylate Chemical class 0.000 abstract 1
- QNKIFGXUKZAWLR-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(C)=O QNKIFGXUKZAWLR-UHFFFAOYSA-N 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000113 | 2020-03-26 | ||
| PCT/IB2021/052486 WO2021191838A1 (en) | 2020-03-26 | 2021-03-25 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221836A1 true PE20221836A1 (es) | 2022-11-29 |
Family
ID=89666363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002114A PE20221836A1 (es) | 2020-03-26 | 2021-03-25 | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240067637A1 (https=) |
| EP (1) | EP4126859A1 (https=) |
| JP (1) | JP7805946B2 (https=) |
| KR (1) | KR20220160061A (https=) |
| CN (1) | CN115348962A (https=) |
| AR (1) | AR121666A1 (https=) |
| AU (1) | AU2021244926A1 (https=) |
| BR (1) | BR112022019128A2 (https=) |
| CA (1) | CA3171441A1 (https=) |
| CL (1) | CL2022002568A1 (https=) |
| CO (1) | CO2022014877A2 (https=) |
| CU (1) | CU24714B1 (https=) |
| EC (1) | ECSP22082367A (https=) |
| GE (2) | GEP20257761B (https=) |
| IL (1) | IL296716A (https=) |
| JO (1) | JOP20220219A1 (https=) |
| MX (1) | MX2022011933A (https=) |
| PE (1) | PE20221836A1 (https=) |
| PH (1) | PH12022552340A1 (https=) |
| TW (1) | TWI901650B (https=) |
| WO (1) | WO2021191838A1 (https=) |
| ZA (1) | ZA202211414B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231691B1 (hu) * | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| WO2007042420A1 (en) * | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Isoxazole derivatives |
| KR101103129B1 (ko) | 2005-11-09 | 2012-01-04 | 에프. 호프만-라 로슈 아게 | 3-아릴-아이속사졸-4-카본일-벤조퓨란 유도체 |
| HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| CA2828578A1 (en) * | 2011-03-04 | 2012-09-13 | Lexicon Pharmaceuticals, Inc. | Mst1 kinase inhibitors and methods of their use |
| EP2937349B1 (en) | 2011-03-23 | 2016-12-28 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001278A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| US9475797B2 (en) | 2012-06-26 | 2016-10-25 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| CA2876778A1 (en) | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN102924452B (zh) | 2012-11-16 | 2015-01-21 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法 |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| NZ760341A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US9296747B1 (en) * | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| RU2018101897A (ru) * | 2015-06-22 | 2019-07-24 | Сумитомо Дайниппон Фарма Ко., Лтд. | Бициклическое гетероциклическое амидное производное |
| JP2018525429A (ja) | 2015-08-28 | 2018-09-06 | アッヴィ・インコーポレイテッド | Ｓ１ｐ調節剤としての縮合複素環化合物 |
| HRP20221098T1 (hr) | 2016-03-18 | 2022-11-25 | Uwm Research Foundation, Inc. | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 |
| ES2910110T3 (es) | 2016-12-08 | 2022-05-11 | Hoffmann La Roche | Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A |
| US20200268728A1 (en) * | 2016-12-20 | 2020-08-27 | Sumitomo Dainippon Pharma Co., Ltd. | Drug targeting cancer stem cell |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| DK3717488T3 (da) | 2017-11-27 | 2021-12-13 | Dart Neuroscience Llc | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| IL279266B2 (en) | 2018-06-13 | 2024-03-01 | Hoffmann La Roche | New isoxazolyl ether derivatives as gaba a alpha5 pam |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
-
2021
- 2021-03-11 TW TW110108696A patent/TWI901650B/zh active
- 2021-03-25 CN CN202180023958.0A patent/CN115348962A/zh active Pending
- 2021-03-25 GE GEAP202116066A patent/GEP20257761B/en unknown
- 2021-03-25 BR BR112022019128A patent/BR112022019128A2/pt unknown
- 2021-03-25 GE GEAP202416066A patent/GEAP202416066A/en unknown
- 2021-03-25 AU AU2021244926A patent/AU2021244926A1/en active Pending
- 2021-03-25 KR KR1020227037372A patent/KR20220160061A/ko active Pending
- 2021-03-25 PE PE2022002114A patent/PE20221836A1/es unknown
- 2021-03-25 JP JP2022557102A patent/JP7805946B2/ja active Active
- 2021-03-25 US US17/907,174 patent/US20240067637A1/en active Pending
- 2021-03-25 PH PH1/2022/552340A patent/PH12022552340A1/en unknown
- 2021-03-25 EP EP21715334.5A patent/EP4126859A1/en active Pending
- 2021-03-25 CU CU2022000058A patent/CU24714B1/es unknown
- 2021-03-25 MX MX2022011933A patent/MX2022011933A/es unknown
- 2021-03-25 WO PCT/IB2021/052486 patent/WO2021191838A1/en not_active Ceased
- 2021-03-25 IL IL296716A patent/IL296716A/en unknown
- 2021-03-25 CA CA3171441A patent/CA3171441A1/en active Pending
- 2021-03-26 AR ARP210100754A patent/AR121666A1/es unknown
-
2022
- 2022-09-13 JO JOP/2022/0219A patent/JOP20220219A1/ar unknown
- 2022-09-22 CL CL2022002568A patent/CL2022002568A1/es unknown
- 2022-10-18 ZA ZA2022/11414A patent/ZA202211414B/en unknown
- 2022-10-19 CO CONC2022/0014877A patent/CO2022014877A2/es unknown
- 2022-10-22 EC ECSENADI202282367A patent/ECSP22082367A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220160061A (ko) | 2022-12-05 |
| ECSP22082367A (es) | 2022-11-30 |
| CN115348962A (zh) | 2022-11-15 |
| JP7805946B2 (ja) | 2026-01-26 |
| CU24714B1 (es) | 2024-07-10 |
| GEP20257761B (en) | 2025-04-10 |
| CA3171441A1 (en) | 2021-09-30 |
| GEAP202416066A (en) | 2024-12-10 |
| US20240067637A1 (en) | 2024-02-29 |
| JP2023520647A (ja) | 2023-05-18 |
| TW202202495A (zh) | 2022-01-16 |
| PH12022552340A1 (en) | 2023-11-29 |
| JOP20220219A1 (ar) | 2022-09-13 |
| AR121666A1 (es) | 2022-06-29 |
| EP4126859A1 (en) | 2023-02-08 |
| CO2022014877A2 (es) | 2022-10-31 |
| TWI901650B (zh) | 2025-10-21 |
| BR112022019128A2 (pt) | 2022-11-08 |
| IL296716A (en) | 2022-11-01 |
| ZA202211414B (en) | 2023-06-28 |
| MX2022011933A (es) | 2022-10-20 |
| WO2021191838A1 (en) | 2021-09-30 |
| CU20220058A7 (es) | 2023-05-11 |
| CL2022002568A1 (es) | 2023-03-24 |
| AU2021244926A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12459958B2 (en) | Tricyclic compounds as HPK1 inhibitor and the use thereof | |
| AU2011258217B2 (en) | Heteroaryl compounds and methods of use thereof | |
| US9695171B2 (en) | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | |
| CA2878054C (en) | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors | |
| US20170073343A1 (en) | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | |
| WO2013042137A1 (en) | Bicyclic heterocycles as irak4 inhibitors | |
| JP6515175B2 (ja) | 芳香族ヘテロ環誘導体及びその医薬的適用 | |
| EP3083589A1 (en) | Substituted piperazine compounds and methods of use thereof | |
| PE20221836A1 (es) | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 | |
| JP2020505397A (ja) | Ｌｒｒｋ２キナーゼ活性を阻害するための化合物 | |
| AU2017213498A1 (en) | Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system | |
| JP6345651B2 (ja) | ヘテロアリール化合物及びその使用方法 | |
| CN104496987B (zh) | 取代杂环类化合物及其在药物上的应用 | |
| OA22045A (en) | APOL1 inhibitors and methods of use. | |
| TW202402751A (zh) | 鐵死亡調節物、製劑及其使用 |